If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Belize is a full participating member of the United Nations; the Commonwealth of Nations; the Organization of American States (OAS); the Central American Integration System (SICA); the Caribbean Community (CARICOM); the CARICOM Single Market and Economy (CSME); the Association of Caribbean States (ACS); and the Caribbean Court of Justice (CCJ), which currently serves as a final court of appeal for only Barbados, Belize, Dominica, Guyana and Saint Lucia. In 2001, the Caribbean Community heads of government voted on a measure declaring that the region should work towards replacing the UK's Judicial Committee of the Privy Council as final court of appeal with the Caribbean Court of Justice. It is still in the process of acceding to CARICOM treaties including the trade and single market treaties.
=== Differential diagnosis === Cervical radiculopathy can also cause paresthesia and abnormal sensibility in the hands and wrist. The distribution usually follows the nerve root, and the paresthesia may be provoked by neck movement. Electromyography and imaging of the cervical spine can help to differentiate cervical radiculopathy from carpal tunnel syndrome if the diagnosis is unclear. Carpal tunnel syndrome is sometimes applied as a label to anyone with pain, numbness, swelling, or burning in the radial side of the hands or wrists. When pain is the primary symptom, carpal tunnel syndrome is unlikely to be the source of the symptoms. When the symptoms and signs point to atrophy and muscle weakness more than numbness, consider neurodegenerative disorders such as Amyotrophic Lateral Sclerosis or Charcot-Marie Tooth.
Continuous ion sources (most commonly electrospray ionization, ESI) are generally interfaced to the TOF mass analyzer by "orthogonal extraction" in which ions introduced into the TOF mass analyzer are accelerated along the axis perpendicular to their initial direction of motion. Orthogonal acceleration combined with collisional ion cooling allows separating the ion production in the ion source and mass analysis. In this technique, very high resolution can be achieved for ions produced in MALDI or ESI sources. Before entering the orthogonal acceleration region or the pulser, the ions produced in continuous (ESI) or pulsed (MALDI) sources are focused (cooled) into a beam of 1–2 mm diameter by collisions with a residual gas in RF multipole guides. A system of electrostatic lenses mounted in high-vacuum region before the pulser makes the beam parallel to minimize its divergence in the direction of acceleration. The combination of ion collisional cooling and orthogonal acceleration TOF has provided significant increase in resolution of modern TOF MS from few hundred to several tens of thousand without compromising the sensitivity.
=== Impact on nutrition === The introduction of refrigeration allowed for the hygienic handling and storage of perishables, and as such, promoted output growth, consumption, and the availability of nutrition. The change in our method of food preservation moved us away from salts to a more manageable sodium level. The ability to move and store perishables such as meat and dairy led to a 1.7% increase in dairy consumption and overall protein intake by 1.25% annually in the US after the 1890s. People were not only consuming these perishables because it became easier for they themselves to store them, but because the innovations in refrigerated transportation and storage led to less spoilage and waste, thereby driving the prices of these products down. Refrigeration accounts for at least 5.1% of the increase in adult stature (in the US) through improved nutrition, and when the indirect effects associated with improvements in the quality of nutrients and the reduction in illness is additionally factored in, the overall impact becomes considerably larger. Recent studies have also shown a negative relationship between the number of refrigerators in a household and the rate of gastric cancer mortality.
When urine pH is abnormal, the urinary recovery of amphetamine may range from a low of 1% to a high of 75%, depending mostly upon whether urine is too basic or acidic, respectively. Following oral administration, amphetamine appears in urine within 3 hours. Roughly 90% of ingested amphetamine is eliminated 3 days after the last oral dose. CYP2D6, dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), butyrate-CoA ligase (XM-ligase), and glycine N-acyltransferase (GLYAT) are the enzymes known to metabolize amphetamine or its metabolites in humans. Amphetamine has a variety of excreted metabolic products, including 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, N-hydroxyamphetamine, benzoic acid, hippuric acid, norephedrine, and phenylacetone. Among these metabolites, the active sympathomimetics are 4-hydroxyamphetamine, 4-hydroxynorephedrine, norephedrine, and N-hydroxyamphetamine. The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways, detectable metabolites, and metabolizing enzymes in humans include the following:
Sources: en.wikipedia.org
== History == In ancient history, Hippocrates discussed bile pigments in two of the four humours in the context of a relationship between yellow and black biles. Hippocrates visited Democritus in Abdera who was regarded as the expert in melancholy "black bile". Relevant documentation emerged in 1827 when M. Louis Jacques Thénard examined the biliary tract of an elephant that had died at a Paris zoo. He observed dilated bile ducts were full of yellow magma, which he isolated and found to be insoluble in water. Treating the yellow pigment with hydrochloric acid produced a strong green color. Thenard suspected the green pigment was caused by impurities derived from mucus of bile. Leopold Gmelin experimented with nitric acid in 1826 to establish the redox behavior in change from bilirubin to biliverdin, although the nomenclature did not exist at the time. The term biliverdin was coined by Jöns Jacob Berzelius in 1840, although he preferred "bilifulvin" (yellow/red) over "bilirubin" (red). The term "bilirubin" was thought to have become mainstream based on the works of Staedeler in 1864 who crystallized bilirubin from cattle gallstones. Rudolf Virchow in 1847 recognized hematoidin to be identical to bilirubin.
It develops most often only after prolonged (months, years or even decades) exposure to antidopaminergics. Extrapyramidal side effects. Motor symptoms such as tremor, parkinsonism, involuntary movements, reduced ability to move one's voluntary muscles, etc. Unknown incidence or relationship to drug treatment adverse effects include:
A motorcyclist since his youth, in 2004 McGregor undertook an international motorcycling trip with his best friend Charley Boorman, accompanied by cameraman Claudio von Planta and a support crew. From mid-April to the end of July, they travelled from London to New York City via central Europe, Ukraine, Kazakhstan, Mongolia, Russia, Canada, and the United States on BMW R1150GS motorcycles, over a cumulative distance of 22,345 miles (35,960 km). The trip included visits to several UNICEF programmes along the route, and formed the basis of a television series and a best-selling book, both called Long Way Round. McGregor and Boorman reunited with this team in 2007 for another international motorcycle trip, from John o' Groats in Scotland to Cape Town in South Africa. The journey lasted from May until August, and yielded another book and TV series, titled Long Way Down. McGregor appeared in a two-part BBC documentary in 2012 entitled Ewan McGregor: Cold Chain Mission in which he travels by motorbike, boat, plane, and foot to deliver vaccines to children in remote parts of India, Nepal and the Republic of Congo. The trip was part of his work as a UNICEF Ambassador. In 2019, McGregor and Boorman – with their principal support crew from the previous two Long Way journeys – undertook a third international trip, this time on Harley-Davidson LiveWire electric motorcycles. From September to December, they rode from Patagonia, Argentina to California, United States, which was documented in the 2020 series Long Way Up.
==== Available forms ==== Adderall is available as immediate-release (IR) tablets and extended-release (XR) capsules. Mydayis is available as an extended-release formulation. Adderall XR is approved to treat attention deficit hyperactivity disorder for up to 12 hours in individuals 6 years and older and uses a double-bead formulation. The capsule can be swallowed like a tablet, or it can be opened and the beads sprinkled over applesauce for comparable absorption. Upon ingestion, half of the beads provide immediate administration of medication, while the other half are enveloped in a coating that must dissolve, delaying absorption of its contents. It is designed to provide a therapeutic effect and plasma concentrations identical to taking two doses of Adderall IR four hours apart. Mydayis uses a longer-lasting triple-bead formulation and is approved to treat attention deficit hyperactivity disorder for up to 16 hours in individuals aged 13 years of age and older. In the United States, the immediate and extended-release formulations of Adderall are available as generic medications. Generic formulations of Mydayis became available in the US in October 2023.
14E PATRIOT Fire Control Enhanced Operator/Maintainer 14G Air Defense Battle Management System Operator 14H Air Defense Enhanced Early Warning System Operator 14P Air and Missile Defense Crewmember 14S Avenger Crewmember 14T PATRIOT Launching Station Enhanced Operator/Maintainer 14U Air Defense Artillery Recruit 14Z Air Defense Artillery (ADA) Senior Sergeant
Sources: en.wikipedia.org
== Genetic engineering of metabolic pathways == Many metabolic pathways are of commercial interest. For instance, the production of many antibiotics or other drugs requires complex pathways. The pathways to produce such compounds can be transplanted into microbes or other more suitable organism for production purposes. For example, the world's supply of the anti-cancer drug vinblastine is produced by relatively ineffient extraction and purification of the precursors vindoline and catharanthine from the plant Catharanthus roseus, which are then chemically converted into vinblastine. The biosynthetic pathway to produce vinblastine, including 30 enzymatic steps, has been transferred into yeast cells which is a convenient system to grow in large amounts. With these genetic modifications yeast can use its own metabolites geranyl pyrophosphate and tryptophan to produce the precursors of catharanthine and vindoline. This process required 56 genetic edits, including expression of 34 heterologous genes from plants in yeast cells.
Acral angiofibromas are also termed superficial acral fibromyxomas, digital fibromyxomas, acquired digital fibrokeratomas, acquired periungual fibrokeratomas, garlic clove fibromas, digital fibromas, and cellular digital fibromas. At one time, periungual angiofibromas were regarded as a type of acral angiofibroma (see above description). Acral refers to distal sites of the ears, nose, hands, fingers, feet, and toes. Acral angifibromeae occur primarily in areas close to the nails of fingers and toes (~80% of cases) or, less commonly, palms of the hands or soles of the feet. The tissues of this tumor consists of bland spindle-shaped and star-shaped cells within a collagen fiber-rich stroma containing prominent blood vessels and mast cells.
The perichondrium (from Greek περί, peri, 'around' and χόνδρος, chondros, 'cartilage') is a layer of dense irregular connective tissue that surrounds the cartilage of developing bone. It consists of two separate layers: an outer fibrous layer and inner chondrogenic layer. The fibrous layer contains fibroblasts, which produce collagenous fibres. The chondrogenic layer remains undifferentiated and can form chondroblasts. Perichondrium can be found around the perimeter of elastic cartilage and hyaline cartilage. Perichondrium is a type of irregular collagenous ordinary connective tissue, and also functions in the growth and repair of cartilage. Perichondrium contains type I collagen and type XII collagen.
== History == Van Gieson’s stain was first described by Ira T. Van Gieson in 1889 as a method for examining nervous system tissue. Van Gieson was a pathologist who published The Laboratory notes of technical methods for the nervous system in 1889, introducing the picric–fuchsin method at that time. In early 20th century the stain was combined with other techniques. In 1908, Friedrich hermann verhoeff introduced an iron–hematoxylin stain for elastic fibers, which used with Van Gieson’s counterstain to form the Verhoeff–Van Gieson (VVG) stain. In VVG staining, elastic fibers are stained black (by Verhoeff’s hematoxylin), collagen appears red (by Van Gieson), and cytoplasm elements are yellow.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.